Personal information

No personal information available

Activities

Works (16)

Data from Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study

2023-04-01 | Preprint
Contributors: Nai-Jung Chiang; Kien Thiam Tan; Li-Yuan Bai; Chin-Fu Hsiao; Chung-Yu Huang; Yi-Ping Hung; Chien-Jui Huang; San-Chi Chen; Yan-Shen Shan; Yee Chao et al.
Source: check_circle
Crossref

Data from Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study

2023-04-01 | Preprint
Contributors: Nai-Jung Chiang; Kien Thiam Tan; Li-Yuan Bai; Chin-Fu Hsiao; Chung-Yu Huang; Yi-Ping Hung; Chien-Jui Huang; San-Chi Chen; Yan-Shen Shan; Yee Chao et al.
Source: check_circle
Crossref

Supplementary Figure from Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study

2023-04-01 | Preprint
Contributors: Nai-Jung Chiang; Kien Thiam Tan; Li-Yuan Bai; Chin-Fu Hsiao; Chung-Yu Huang; Yi-Ping Hung; Chien-Jui Huang; San-Chi Chen; Yan-Shen Shan; Yee Chao et al.
Source: check_circle
Crossref

Supplementary Figure from Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study

2023-04-01 | Preprint
Contributors: Nai-Jung Chiang; Kien Thiam Tan; Li-Yuan Bai; Chin-Fu Hsiao; Chung-Yu Huang; Yi-Ping Hung; Chien-Jui Huang; San-Chi Chen; Yan-Shen Shan; Yee Chao et al.
Source: check_circle
Crossref

Supplementary Figure from Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study

2023-04-01 | Preprint
Contributors: Nai-Jung Chiang; Kien Thiam Tan; Li-Yuan Bai; Chin-Fu Hsiao; Chung-Yu Huang; Yi-Ping Hung; Chien-Jui Huang; San-Chi Chen; Yan-Shen Shan; Yee Chao et al.
Source: check_circle
Crossref

Supplementary Figure from Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study

2023-04-01 | Preprint
Contributors: Nai-Jung Chiang; Kien Thiam Tan; Li-Yuan Bai; Chin-Fu Hsiao; Chung-Yu Huang; Yi-Ping Hung; Chien-Jui Huang; San-Chi Chen; Yan-Shen Shan; Yee Chao et al.
Source: check_circle
Crossref

Supplementary Figure from Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study

2023-04-01 | Preprint
Contributors: Nai-Jung Chiang; Kien Thiam Tan; Li-Yuan Bai; Chin-Fu Hsiao; Chung-Yu Huang; Yi-Ping Hung; Chien-Jui Huang; San-Chi Chen; Yan-Shen Shan; Yee Chao et al.
Source: check_circle
Crossref

Supplementary Figure from Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study

2023-04-01 | Preprint
Contributors: Nai-Jung Chiang; Kien Thiam Tan; Li-Yuan Bai; Chin-Fu Hsiao; Chung-Yu Huang; Yi-Ping Hung; Chien-Jui Huang; San-Chi Chen; Yan-Shen Shan; Yee Chao et al.
Source: check_circle
Crossref

Supplementary Figure from Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study

2023-04-01 | Preprint
Contributors: Nai-Jung Chiang; Kien Thiam Tan; Li-Yuan Bai; Chin-Fu Hsiao; Chung-Yu Huang; Yi-Ping Hung; Chien-Jui Huang; San-Chi Chen; Yan-Shen Shan; Yee Chao et al.
Source: check_circle
Crossref

Supplementary Figure from Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study

2023-04-01 | Preprint
Contributors: Nai-Jung Chiang; Kien Thiam Tan; Li-Yuan Bai; Chin-Fu Hsiao; Chung-Yu Huang; Yi-Ping Hung; Chien-Jui Huang; San-Chi Chen; Yan-Shen Shan; Yee Chao et al.
Source: check_circle
Crossref

Supplementary Figure from Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study

2023-04-01 | Preprint
Contributors: Nai-Jung Chiang; Kien Thiam Tan; Li-Yuan Bai; Chin-Fu Hsiao; Chung-Yu Huang; Yi-Ping Hung; Chien-Jui Huang; San-Chi Chen; Yan-Shen Shan; Yee Chao et al.
Source: check_circle
Crossref

Supplementary Figure from Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study

2023-04-01 | Preprint
Contributors: Nai-Jung Chiang; Kien Thiam Tan; Li-Yuan Bai; Chin-Fu Hsiao; Chung-Yu Huang; Yi-Ping Hung; Chien-Jui Huang; San-Chi Chen; Yan-Shen Shan; Yee Chao et al.
Source: check_circle
Crossref

Supplementary Table from Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study

2023-04-01 | Preprint
Contributors: Nai-Jung Chiang; Kien Thiam Tan; Li-Yuan Bai; Chin-Fu Hsiao; Chung-Yu Huang; Yi-Ping Hung; Chien-Jui Huang; San-Chi Chen; Yan-Shen Shan; Yee Chao et al.
Source: check_circle
Crossref

Supplementary Table from Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study

2023-04-01 | Preprint
Contributors: Nai-Jung Chiang; Kien Thiam Tan; Li-Yuan Bai; Chin-Fu Hsiao; Chung-Yu Huang; Yi-Ping Hung; Chien-Jui Huang; San-Chi Chen; Yan-Shen Shan; Yee Chao et al.
Source: check_circle
Crossref

A generational comparison for unfavorable cancer of unknown primary in a single institute over 20 years

Cancer Medicine
2023-01 | Journal article
Contributors: Cheng‐Yu Tang; Jen‐Fan Hang; Yi‐Ping Hung; Nai‐Chi Chiu; Jiun‐I Lai; Ming‐Huang Chen; Chun‐Yu Liu; Muh‐Hwa Yang; Yee Chao; Peter Mu‐Hsin Chang
Source: check_circle
Crossref

Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study

Clinical Cancer Research
2022-10-03 | Journal article
Contributors: Nai-Jung Chiang; Kien Thiam Tan; Li-Yuan Bai; Chin-Fu Hsiao; Chung-Yu Huang; Yi-Ping Hung; Chien-Jui Huang; San-Chi Chen; Yan-Shen Shan; Yee Chao et al.
Source: check_circle
Crossref